NCT05317416 2026-04-16
MagnetisMM-7
Pfizer
Phase 3 Active not recruiting
Clinical Trials
35 trialsNCT06152575 2026-04-16
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Pfizer
Phase 3 Recruiting
NCT05623020 2026-04-15
MagnetisMM-6
Pfizer
Phase 3 Recruiting
NCT06182774 2026-04-14
Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT06615479 2026-04-14
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Recruiting
NCT03301220 2026-04-13
A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT03901963 2026-04-13
AURIGA
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04181827 2026-04-13
CARTITUDE-4
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04923893 2026-04-13
CARTITUDE-5
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05083169 2026-04-13
MajesTEC-3
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05438043 2026-04-13
A Study of Daratumumab
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT05455320 2026-04-13
MonumenTAL-3
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05552222 2026-04-13
MajesTEC-7
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT05572515 2026-04-13
MajesTEC-9
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT07258511 2026-04-13
TRIlogy-4
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT07518186 2026-04-13
TRIlogy-5
Janssen Research & Development, LLC
Phase 3 Not yet recruiting
NCT03652064 2026-04-08
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT03993912 2026-04-07
IFM2017_03
University Hospital, Lille
Phase 3 Active not recruiting
NCT04512235 2026-04-07
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
Alexion Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT00430365 2026-04-06
IFM2005-02
University Hospital, Toulouse
Phase 3 Completed
NCT01191060 2026-04-06
IFM/DFCI2009
University Hospital, Toulouse
Phase 3 Completed
NCT06980480 2026-04-06
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Takeda
Phase 3 Recruiting
NCT03937635 2026-04-03
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT04566328 2026-04-03
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT04975997 2026-04-03
EXCALIBER-RRMM
Celgene
Phase 3 Active not recruiting
NCT06918002 2026-04-02
ElLen
Intergroupe Francophone du Myelome
Phase 3 Recruiting
NCT05552976 2026-04-01
SUCCESSOR-2
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT04162210 2026-03-31
DREAMM-3
GlaxoSmithKline
Phase 3 Active not recruiting
NCT05020236 2026-03-27
MAGNETISMM-5
Pfizer
Phase 3 Recruiting
NCT06413498 2026-03-27
iMMagine-3
Gilead Sciences
Phase 3 Recruiting
NCT05243797 2026-03-25
MajesTEC-4
European Myeloma Network B.V.
Phase 3 Recruiting
NCT06932562 2026-03-25
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
European Myeloma Network B.V.
Phase 3 Recruiting
NCT07452198 2026-03-25
A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT05519085 2026-03-24
SUCCESSOR-1
Celgene
Phase 3 Recruiting
NCT03844048 2026-03-20
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
AbbVie
Phase 3 Active not recruiting